Cargando…

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Detalles Bibliográficos
Autores principales:	Djebbari, Faouzi, Panitsas, Fotios, Eyre, Toby A., Prodger, Catherine, Davies, Fearn, Burton, Kieran, Khera, Akhil, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Peniket, Andy, Ramasamy, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556501/ https://www.ncbi.nlm.nih.gov/pubmed/33054067 http://dx.doi.org/10.3324/haematol.2019.240762

Ejemplares similares

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients
por: Djebbari, Faouzi, et al.
Publicado: (2022)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients
por: Djebbari, Faouzi, et al.
Publicado: (2020)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review
por: Eyre, Toby A., et al.
Publicado: (2020)

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
por: Maouche, Nadjoua, et al.
Publicado: (2022)

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
por: Djebbari, Faouzi, et al.
Publicado: (2022)

Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol
por: Djebbari, Faouzi, et al.
Publicado: (2017)

Correction: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era
por: Sharpley, F. A., et al.
Publicado: (2019)

A systematic review of non-standard dosing of oral anticancer therapies
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)
por: Panitsas, Fotios P, et al.
Publicado: (2004)

Multiple myeloma in the very elderly patient: challenges and solutions
por: Willan, John, et al.
Publicado: (2016)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Effect of Mailed Fecal Immunochemical Test Outreach for Patients Newly Eligible for Colorectal Cancer Screening
por: Burns, Shohei, et al.
Publicado: (2023)

Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
por: Shen, Miles, et al.
Publicado: (2022)

Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era
por: Sharpley, F. A., et al.
Publicado: (2019)

Periodontal and systemic health of morbidly obese patients eligible for bariatric surgery: a cross-sectional study
por: Čolak, Dejana, et al.
Publicado: (2022)

Impact of Medicaid expansion on smoking prevalence and quit attempts among those newly eligible, 2011–2019
por: Hilts, Katy Ellis, et al.
Publicado: (2021)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Satisfaction with Health Care of Dually Eligible Older Beneficiaries
por: Burton, Lynda C., et al.
Publicado: (2001)

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
por: Nargesi, Arash A., et al.
Publicado: (2021)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
por: Udwadia, Zarir F., et al.
Publicado: (2019)

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2020)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Eligibility for the kidney transplant wait list: a model for conceptualizing patient risk
por: Kiberd, Bryce A, et al.
Publicado: (2014)

Elige la autoestima /
por: Aguilar Kubli, Eduardo
Publicado: (1995)

Eligible Vehicles for Quinine
Publicado: (1890)

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
por: Eyre, Toby A, et al.
Publicado: (2015)

Preoperative Glycated Haemoglobin Level and Postoperative Morbidity and Mortality in Patients Scheduled for Liver Transplant
por: Parveez, Mohd Qurram, et al.
Publicado: (2019)

Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT
por: Eyre, Toby A., et al.
Publicado: (2021)

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
por: Zeng, Zi-Hang, et al.
Publicado: (2017)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

The criteria of eligibility to the extracorporeal treatment
por: Zangrillo, A
Publicado: (2012)

Use of outpatient care in VA and Medicare among disability-eligible and age-eligible veteran patients
por: Liu, Chuan-Fen, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_409gf860p1o5fo3dgu87ea1qub